Written from the studies on PubMed, searched on 2026. nov. 12.. Every number below comes from a study listed under Sources. The text was written by AI from these studies; each sentence names the studies it comes from.
The claim
Posts say a drug for Gaucher disease can be used against cancer.
Where research stands
We found 2 published papers on eliglustat and cancer. They were published between 2015 and 2024. 1 of them is a study in people. In all, 31 people took part. None of them compared people who got it with a group that did not. 1 was a study in animals, and none was only in cells in the lab.
- 1In people
- 1In animals
- 0Only in the lab
What the studies found
Other studies in people
One small early test in people used eliglustat with an immune therapy drug. [1] It included 31 people with advanced cancers. [1] It mainly checked safety, and the authors say that goal was met. [1] The authors say 22.6% of patients responded to the treatment. [1] There was no comparison group, so we cannot tell what eliglustat added. [1]
In animals
Long studies in mice and rats checked if eliglustat itself causes cancer. [2] The authors say it did not increase the number of tumours. [2] These studies looked at safety, not at treating cancer. [2]
In the lab
The same authors report lab and animal tumour work. [1] Eliglustat made cancer cells show more signals to immune cells. [1] Results in animals do not always hold in people.
Verdict
Only one small early test in people exists, and it had no comparison group. [1] The animal studies were about safety, not about treating cancer, so the claim is unproven. [2]
Unproven means: it was only tested in animals or cells, or there is too little or mixed data from people. How we rate claims
What this means for you: A study in people is not proof that it helps you. Do not stop or change your medicines because of it. Ask your doctor before you start taking it.
Sources
- Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial.2024 · Nat Commun · Study in people
- Carcinogenicity testing of eliglustat in mice and rats.2015 · Regul Toxicol Pharmacol · In animals